Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Privacy Policy

Thank you for visiting the Avalanche Biotechnologies website and for reviewing our privacy policy. The following statement explains our policy regarding personal information you may supply when visiting our website: Avalanche Biotechnologies does not sell, rent, or share information with any other organization. We do not transfer information for any promotional or marketing purposes, nor is that information shared with any third parties whatsoever. Our website contains links to other sites. We are not responsible for the privacy practices of these websites.

Avalanche Biotechnologies Announces Appointment of Samuel B. Barone, M.D., as Chief Medical Officer

July 1, 2014

MENLO PARK, Calif., July 1, 2014 -- Avalanche Biotechnologies, Inc., a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the appointment of Samuel B. Barone, M.D. in the role of Chief Medical Officer. Dr. Barone will lead the company’s clinical development programs, including advancing Avalanche’s lead product, AVA-101 for the treatment of wet AMD. Dr. Barone will report to Thomas Chalberg, Ph.D., Avalanche’s Co-Founder and Chief Executive Officer.

Read More

Read All Avalanche News